share_log

XCan-Fite Partner Vetbiolix Accelerate Piclidenoson Development With Clinical Trial For Canine Osteoarthritis

Benzinga ·  Mar 20 13:49

Can-Fite's upfront and royalties on sales upon regulatory approval of Piclidenoson for veterinary use, is projected to be $325 million in the aggregate over the next decade assuming a 2029 launch

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Comment Comment · Views 312

Recommended

Write a comment